Micelle BioPharma, Inc. is an integrated pharmaceutical company that focuses on developing and marketing a variety of products, including those based on the proprietary Advanced Lipid Technologies (ALT) platform. The ALT platform refers to several unique drug delivery systems designed to improve the bodys ability to absorb and use lipophilic compounds such as fatty acids, hormones, several vitamins, and many active pharmaceutical ingredients (APIs). Because they do not dissolve in water, and instead are absorbed with fats, the bioavailability and usefulness of these potentially beneficial compounds as APIs for treating diseases is often limited. Micelle recognizes the significant unmet need within the pharmaceutical industry for a means by which lipophilic compounds can be effectively absorbed by the body. Micelles lipid chemists, biologists, formulation scientists, and medical doctors continue to develop the ALT platform, which increases absorption of lipophilic drugs and nutrients while mitigating the dependency on the fat content of the food (food effect) that is seen with many other lipophilic drug delivery systems. Micelle leverages the ALT platform to create unique products that, if approved by the Food and Drug Administration (FDA), would target disorders and diseases that might be correctable by restoring the bodys natural lipid balance. In addition to our primary goal of developing proprietary pharmaceutical products through the use of ALT technology, we also offer services to third parties. Micelle offers product development, manufacturing of soft gel capsules, and contract product sales. For certain development projects, Micelle may partner with a third party to leverage the ALT platform for delivery of a third partys lipophilic compound. Micelle believes in being a part of the local community and actively participates in several municipal and charity organizations and events.